Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer–Related Lymphedema and Local Tumor Control
- Neratinib Plus Capecitabine in HER2+ MBC Previously Treated With ≥2 HER2-Directed Regimens
- Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer
- FDA Approves Breast Cancer Treatment That Can Be Administered at Home by Health Care Professional
- FDA Approves Pembrolizumab for Adults and Children With TMB-H Solid Tumors
- ctDNA Markers of Progression in Advanced Breast Cancer Treated With Fulvestrant With or Without Palbociclib
- ASCO: Alpelisib Plus Fulvestrant for PIK3CA-Mutated Breast Cancer After Failure of CDK4/6 Inhibitors
- Tucatinib Plus Trastuzumab and Capecitabine for Patients With HER2-Positive Breast Cancer and Brain Metastases
- The Effect of Adjuvant Treatment in Small Node-Negative HER2-Positive Breast Cancer
- [18F]FDG PET/CT in the Staging of Inflammatory Breast Cancer